Ovid Therapeutics advances OV329 epilepsy drug, secures $60M funding

March 18, 2026 6:05 AM

Ovid Therapeutics Inc. (NASDAQ: OVID) reported favorable safety and tolerability results from a 7 mg dose of its experimental epilepsy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found